Aviado · Research
Longevity Daily
Wednesday, May 20, 2026
Listen
Today's Brief
Brain longevity leads today, anchored by new findings on a centenarian gene that may guard against Alzheimer's through enhanced DNA repair — and a look at whether GLP-1 drugs are becoming the next brain aging tool. The Oxford Longevity Project makes the bold claim that 80% of age-related ill health is within individual control. On the supplements front, krill oil earns a fresh look after a 12-week pilot in older adults showed meaningful pain and mobility signals. Plus: the Greenland shark genome — sequenced for the first time — reveals cancer resistance and DNA repair strategies from Earth's longest-lived vertebrate.
10 stories2 peer-reviewed2 trials
Cognitive Health & Neuroprotection
Centenarian 'Longevity Gene' May Shield the Aging Brain from Alzheimer's — via DNA Repair
A specific gene variant found in people who live past 100 may protect the brain from Alzheimer's disease by enhancing the cell's ability to repair damaged DNA, according to new research. Carriers of this gene showed reduced hallmarks of neurodegeneration, suggesting the same biological mechanism that enables extreme old age may directly counteract cognitive decline. This matters because it points toward DNA repair pathways — not just amyloid clearance — as a viable target for Alzheimer's prevention. If validated in larger studies, this could meaningfully shift how researchers prioritize next-generation dementia therapies.
Read more →Your Metabolic 'Biological Age' Correlates Strongly With Dementia Risk, New Clock Study Shows
A new metabolomic aging clock — built from blood metabolite patterns — shows that people who test biologically older than their chronological age face meaningfully higher dementia risk. The finding adds to growing evidence that aging clocks could help identify who needs earlier and more aggressive cognitive interventions, well before symptoms appear. As Fight Aging! notes, the real long-term value of these clocks lies in rapidly evaluating anti-aging therapies — a use case still maturing but increasingly within reach.
Read more →GLP-1 Drugs Could Become Brain Longevity Agents — If They Can Cross the Blood-Brain Barrier
GLP-1 receptor agonists have shown early signals of benefit in neurodegenerative disease, driven by deep links between metabolic dysfunction and brain aging — but several high-profile trials have returned mixed results. Researchers point to the blood-brain barrier as the key obstacle: some GLP-1 formulations penetrate it poorly, limiting CNS exposure. This analysis argues the question is no longer whether GLP-1s affect the brain, but how to get them there more reliably — a design challenge with major implications for cognitive aging medicine.
Read more →Supplements & Compounds
12-Week Krill Oil Pilot Shows Early Signals for Pain Reduction and Improved Mobility in Older Adults
A 12-week pilot study in older adults found that krill oil supplementation improved omega-3 status and produced preliminary signals of reduced chronic pain and better mobility support. The phospholipid-bound EPA/DHA in krill oil may offer bioavailability advantages over standard fish oil, particularly for aging-related inflammation in joints and connective tissue. Caveat: this is a pilot study with a small sample — the signal is promising but larger, controlled trials are needed before firm conclusions can be drawn.
Read more →If You Take Metformin, Watch Your B12: Experts Flag a Commonly Overlooked Depletion Risk
Metformin — widely used for type 2 diabetes and increasingly explored as a longevity drug — can reduce vitamin B12 absorption in the gut over time, raising the risk of peripheral nerve damage and subtle cognitive changes if left unmonitored. Experts emphasize that the drug remains one of the safest metabolic medications available, but urge regular B12 testing for anyone on long-term metformin, particularly those over 50, vegans, and people on proton pump inhibitors. If you or someone you know takes metformin, this is a practical prompt to request a B12 panel at the next check-up.
Read more →Research & Papers
Scientists Sequence the Greenland Shark Genome — and Find Longevity Clues in DNA Repair and Cancer Resistance
Researchers have assembled the first chromosome-level genome of the Greenland shark — the longest-lived vertebrate on Earth, with an estimated lifespan of up to 392 years. The analysis reveals expanded gene families tied to immune enhancement, cancer resistance, and DNA repair, alongside unique modifications to chromatin-stabilizing proteins that may underpin the species' extraordinary longevity. Most intriguing is a newly identified link between ferroptosis regulation and extended lifespan — a potential avenue for future human longevity research that warrants follow-up.
Read more →Oxford Report Claims 80% of Age-Related Ill Health Comes Down to Individual Choices — Here's the Nuance
A new report from the Oxford Longevity Project, presented at the Smart Ageing Summit, argues that individuals bear at least 80% of the responsibility for their health outcomes in old age — far more than genetics or circumstance alone. The empowering core message is broadly consistent with epidemiological evidence on the outsized impact of lifestyle factors, but the 80% figure deserves scrutiny: it risks obscuring the real role of structural factors like healthcare access, poverty, and environmental exposures. Read it for motivation — but bring critical thinking to the specific statistic.
Read more →Lifestyle & Nutrition
How Your Gut Microbiome Shifts from Birth to Old Age — and What Centenarians' Guts Do Differently
A new review in FEBS Letters traces gut microbiome composition across the full human lifespan, from Bifidobacterium dominance in infancy to the distinctive metabolic profiles seen in healthy centenarians. Aging generally erodes core microbial taxa and invites opportunistic species, but centenarians and healthy older adults retain a microbiome that actively buffers against inflammaging — the chronic, low-grade inflammation that drives many age-related diseases. Efforts to build microbiome aging clocks are advancing, though actionable, life-stage-tailored interventions remain an active research frontier rather than established practice.
Read more →Industry & Policy
Canine Longevity Drug Trial Hits 1,000-Dog Enrollment — and It Matters Beyond Veterinary Medicine
The STAY study, evaluating the longevity drug LOY-002 in dogs, has reached its target of 1,000 enrolled canine patients across 70 US veterinary clinics. Dog aging trials serve as an important bridge between preclinical models and human longevity research — dogs share our environment, develop many of the same age-related diseases, and age faster, making them useful proxies for testing interventions. Strong enrollment signals growing momentum for canine longevity science, and results from STAY could accelerate parallel research pathways in humans.
Read more →An Oral GLP-1 Pill Is Now in Clinical Trials — and Could Reshape Access to Metabolic Longevity Medicine
Orforglipron, a recently FDA-approved non-peptide oral GLP-1 receptor agonist, is being evaluated in a clinical trial at CU Anschutz as a weight-loss and metabolic health intervention. Unlike injectable GLP-1s such as semaglutide, a daily pill could significantly broaden access for patients deterred by injections or high costs — a major equity issue given the drugs' expanding role in metabolic and cardiovascular health. For the longevity community, oral GLP-1s represent a potential democratization of metabolic optimization tools that may also benefit brain and cardiovascular aging.
Read more →